Lupin receives approval from USFDA for Bromfenac Ophthalmic Solution
Bromfenac Ophthalmic Solution, 0.07% is indicated for the treatment of postoperative inflammation and reduction of ocular pain
Bromfenac Ophthalmic Solution, 0.07% is indicated for the treatment of postoperative inflammation and reduction of ocular pain
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor
The newly established business will be looking for high-quality, mid- to late-stage assets, clinically focused on the United States market
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
The Product will be manufactured at the company's facility in Bengaluru
First-in-class AKT inhibitor has potential to reshape treatment for breast cancer patients
This innovative solution comes as an answer to the industry-wide challenges of availability, cost, and dependencies linked to custom and proprietary hardware components
Jan Ausahdhi exhibited demonstration stall during 42nd India International Trade Fair to spread awareness
Distributes Ayushman cards to several beneficiaries
Subscribe To Our Newsletter & Stay Updated